Congress Watch archives 2022

From EBCC 2022:
Indirect trial comparison suggests an overall survival advantage with ribociclib over palbociclib in combination with endocrine therapy for postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer

From EBCC 2022:
Neoadjuvant therapy achieves a complete response in the ductal carcinoma in situ component of invasive breast cancer in approximately half of cases

From ESMO Congress 2022:
Patients without evidence of disease after stage IV melanoma surgery or radiotherapy have significantly better overall survival with adjuvant use of nivolumab plus ipilimumab versus placebo

From ESMO Congress 2022:
The PEARLS/KEYNOTE-091 trial points to a disease-free survival advantage with use of adjuvant pembrolizumab after complete resection of stage IB–IIIA NSCLC irrespective of PD-L1 expression

From ESMO Congress 2022:
A study of patients with urachal cancer suggests that the median overall survival duration from this rare tumour type may be longer than previously reported

From ESMO Congress 2022:
Around half of patients with resectable cutaneous squamous cell carcinoma achieved a pathological complete response after 12 weeks of neoadjuvant cemiplimab

From ESMO Congress 2022:
Patients with stage IIIB or IV Merkel cell carcinoma may benefit from nivolumab plus ipilimumab, especially those naïve to immune checkpoint inhibitor therapy

From ESMO Congress 2022:
The KRYSTAL-1 and CodeBreaK 101 studies suggest that metastatic colorectal cancer with a KRAS G12C mutation can be treated with dual targeted therapies

From ESMO Congress 2022:
Patients with EGFR-mutated NSCLC and acquired resistance to first-line osimertinib respond well when later given the tyrosine kinase inhibitor in combination with tepotinib

From ESMO Congress 2022:
Giving streptozotocin–fluorouracil before everolimus may maximise the objective response rate for patients with advanced pancreatic neuroendocrine tumours

From ESMO Congress 2022:
More than half of patients with previously treated HER2-mutant non-small-cell lung cancer responded to treatment with trastuzumab deruxtecan 5.4 mg/kg

From ESMO Congress 2022:
Nivolumab plus ipilimumab after nephrectomy does not extend disease-free survival for high-risk patients with renal cell carcinoma